Clinical trials: HIV Disease
HIV Infections
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.
- Trial name
- NCT00002130
- Testing
- Vesnarinone
- Where
- 2 sites in United States
- Sponsor
- Otsuka America Pharmaceutical
Infection, Human Immunodeficiency Virus
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
ING116070 is a Phase IIIb single-arm, open-label, multicenter study. The study will be conducted in approximately 14 HIV-1 infected antiretroviral therapy (ART)-naïve subjects.
- Trial name
- NCT01499199
- Testing
- Dolutegravir
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- ViiV Healthcare
HIV Infections
The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex
To determine the safety and patient tolerance of UVAR Photopheresis System (extracorporeal photopheresis) in the Treatment of AIDS-Related Complex (ARC).
- Trial name
- NCT00002011
- Testing
- Methoxsalen
- Where
- United States
- Sponsor
- Therakos
AIDS
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
The purpose of this long-term follow-up study is to assess the long-term health status of HIV-infected subjects who previously participated in GSK-sponsored trials evaluating the investigational HIV vaccine 732462.
- Trial name
- NCT01092611
- Testing
- Blood collection, GSK HIV vaccine 732462
- Where
- 41 sites in United States, France and 2 more
- Volunteers
- 190 people
- Sponsor
- GlaxoSmithKline
HIV Infections
A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers
This will be a Phase 1, open-label, parallel group, two-part, single-dose adaptive study in adults with moderate and mild (if needed) hepatic impairment and matched, healthy control subjects with normal hepatic function.
- Trial name
- NCT02354950
- Testing
- GSK1265744 30mg
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/cobicistat (COBI [GS-9350])/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus…
- Trial name
- NCT01106586
- Testing
- Stribild, ATV, Ritonavir
- Where
- 146 sites in United States, Australia and 15 more
- Volunteers
- 708 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus
Kaletra: Therapy With Double Protease Inhibitors
Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants
- Trial name
- NCT01075191
- Where
- 17 sites in Germany
- Volunteers
- 65 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections
Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs
The purpose of this study is to see how safe and effective it is to give multi-drug treatment with indinavir (IDV) plus ritonavir (RTV) plus enteric-coated didanosine (ddI) plus stavudine (d4T) and if there are differences in…
- Trial name
- NCT00006397
- Testing
- Indinavir sulfate, Ritonavir, Stavudine
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Human Immunodeficiency Virus (HIV)-1 Infection
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and…
- Trial name
- NCT00380159
- Testing
- Elvucitabine, Lamivudine, Emtricitabine
- Where
- 7 sites in United States, Dominican Republic and 2 more
- Volunteers
- 4 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infection
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages 3-16 who are failing or…
- Trial name
- NCT00162227
- Testing
- Efavirenz
- Where
- 29 sites in United States, Puerto Rico
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
The primary objective is to establish the pharmacokinetic (PK) profile at steady state of nevirapine XR in HIV infected children from >=3 to <18 years of age.
- Trial name
- NCT00905489
- Testing
- Nevirapine Immediate Release (IR), Nevirapine Extended Release (XR)
- Where
- 10 sites in United States, Botswana and 2 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
PRIMARY: To compare the virologic activity (quantitative RNA PCR, quantitative PBMC) of the combination of nevirapine and zidovudine (AZT) versus AZT alone after 3 and 6 months of treatment.
- Trial name
- NCT00002323
- Testing
- Nevirapine, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Protease Inhibitor
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects
- Trial name
- NCT00357188
- Testing
- Atazanavir Sulphate + Ritonavir, Atazanavir Sulphate + Ritonavir + Efavirenz
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children ≥3 months to <6 years of age.
- Trial name
- PRINCE1 (NCT01099579)
- Testing
- Atazanavir powder, Ritonavir oral solution, Atazanavir capsules
- Where
- 18 sites in Brazil, Chile and 4 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC…
- Trial name
- NCT02469246
- Testing
- F/TAF, ABC/3TC, 3rd ARV agent
- Where
- 80 sites in United States, Belgium and 10 more
- Volunteers
- 567 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection
The purpose of this study is to assess the safety and effectiveness of rilpivirine hydrochloride in combination with other anti-retroviral (ARV) medications for the treatment of ARV-naive (patients who have not been exposed to…
- Trial name
- NCT01692470
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
Cytomegalovirus Infections, HIV Infections
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study
To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate.
- Conditions
- Cytomegalovirus Infections, HIV Infections, Hypocalcemia
- Trial name
- NCT00002146
- Testing
- Magnesium sulfate, Foscarnet sodium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Astra USA
HIV Infections
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment…
- Trial name
- NCT01026727
- Testing
- MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
- Where
- 25 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Myrexis Inc.
HIV Infections
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
To determine the physiological and immunological responses in healthy HIV seronegative adult volunteers vaccinated with a) the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV and b) the Wyeth smallpox…
- Trial name
- NCT00002261
- Testing
- Smallpox Vaccine, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation
This study seeks to assess the virologic effectiveness of dual therapy (lopinavir/ ritonavir (LPV/r) + lamivudine (3TC)) in treatment-experienced human immunodeficiency virus 1 (HIV-1) infected participants with an undetectable…
- Trial name
- SIMPLE (NCT02581202)
- Testing
- lopinavir/ritonavir, lamivudine
- Volunteers
- 216 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.